{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_836"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_836","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"Suppression of the T-cell dependent humoral immune response by Delta(9)-tetrahydrocannanbinol involves inpairment of CD40-CD40 ligand interaction","abstract":"&#916;9-tetrahydrocannabinol (&#916;9-THC), the main psychoactive congener in marijuana, modulates a variety of immunological responses, of which humoral immune responses against T cell antigens are particularly sensitive to suppression by &#916;9-THC. Among different types of contact-mediated B cell activation, the CD40-CD40L interaction between B cells and activated CD4+ T cells plays an important role in all stages involved in plasma cell differentiation. Given that both B cells and activated CD4+ T cells are crucial for T cell-dependent humoral immune response, it is important to assess the effects of &#8710;9-THC on both the indirect suppression of accessory T-cell function and/or the direct suppression of B-cell function. The ultimate goal of this project was to identify potential molecular targets responsible for &#916;9-THC-impairment of signal transduction cascades and gene expression during lymphocyte activation by testing the following hypothesis: &#916;9-THC attenuates the human T cell-dependent IgM antibody response by suppression of CD40L upregulation in activated CD4+ T cells and impairment of the CD40-mediated B cell activation. Therefore, the objectives of the present studies were three-fold; of which the first two objectives focused on T cells, whereas the third objective focused on B cells. The first objective investigated the effects of &#8710;9-THC and the involvement of cannabinoid receptor (CB) 1, CB2, and glucocorticoid receptor (GR) on CD40L expression in mouse splenic T cells. The induction of CD40L on activated mouse splenic CD4+ T cells was differently modulated by &#8710;9-THC, depending on the mode of T cell activation, (i.e., antibodies directed to CD3 and CD28; anti-CD3/CD28 or phorbol ester plus calcium ionophore; PMA/Io). &#8710;9-THC significantly impaired the upregulation of surface CD40L on CD4+ T cells induced by anti-CD3/CD28, but not by PMA/Io. Further, suppression of anti-CD3/CD28-induced CD40L expression in mouse splenic CD4+ T cells by &#8710;9-THC likely occurred at the transcriptional level, independently of CB1, CB2 or GR. The second objective was to investigate the mechanisms by which &#8710;9-THC suppressed CD40L expression by activated primary human CD4+ T cells. Attenuation of anti-CD3/CD28-induced CD40L expression in activated primary human CD4+ T cells by &#8710;9-THC was mediated, at least in part, through suppression of NFAT and NF&#954;B-DNA binding activity. The inhibitory effect of &#916;9-THC on the activation of NFAT and NF&#954;B in primary human CD4+ T cells also involved impairment of Ca2+ elevation without perturbation of proximal T cell receptor signaling events (e.g., tyrosine phosphorylation of ZAP70, Akt, PLC&#947;1/2, and GSK3&#946;). The third objective was to assess the direct effect of &#8710;9-THC on the effector function of primary human B cells using a polyclonal in vitro activation model to generate primary immunoglobulin M (IgM) antibody secreting cells. &#916;9-THC significantly decreased the number of IgM secreting cells, which correlated with the impairment of plasma cell differentiation as evidenced by suppression of immunoglobulin joining chain (IgJ) mRNA expression. &#916;9-THC specifically decreased surface expression of CD80, but not other B cell activation markers (CD69, CD86, and ICAM1). Despite the modest effect on B cell activation, &#916;9-THC profoundly attenuated the proliferation of activated B cells, preventing the progression of B cells toward plasmacytic differentiation. In addition, pretreatment with &#8710;9-THC was accompanied by a robust decrease of STAT3 phosphorylation, whereas the phosphorylation of p65 NF&#954;B subunit was not affected in activated B cells. Collectively, this dissertation research demonstrated that &#8710;9-THC exhibits stimulation- and/or cell type-specific selectivity of NF&#954;B inhibition, and identified several aspects of the multi-faceted mechanism by which &#8710;9-THC suppresses T cell-dependent humoral immunity in humans. A better understanding of the mechanism of cannabinoid-mediated immune function and can be used to address a risk-to-benefit ratio for therapeutic marijuana use.","abstract_html":"&amp;#916;9-tetrahydrocannabinol (&amp;#916;9-THC), the main psychoactive congener in marijuana, modulates a variety of immunological responses, of which humoral immune responses against T cell antigens are particularly sensitive to suppression by &amp;#916;9-THC. Among different types of contact-mediated B cell activation, the CD40-CD40L interaction between B cells and activated CD4+ T cells plays an important role in all stages involved in plasma cell differentiation. Given that both B cells and activated CD4+ T cells are crucial for T cell-dependent humoral immune response, it is important to assess the effects of &amp;#8710;9-THC on both the indirect suppression of accessory T-cell function and/or the direct suppression of B-cell function. The ultimate goal of this project was to identify potential molecular targets responsible for &amp;#916;9-THC-impairment of signal transduction cascades and gene expression during lymphocyte activation by testing the following hypothesis: &amp;#916;9-THC attenuates the human T cell-dependent IgM antibody response by suppression of CD40L upregulation in activated CD4+ T cells and impairment of the CD40-mediated B cell activation. Therefore, the objectives of the present studies were three-fold; of which the first two objectives focused on T cells, whereas the third objective focused on B cells. The first objective investigated the effects of &amp;#8710;9-THC and the involvement of cannabinoid receptor (CB) 1, CB2, and glucocorticoid receptor (GR) on CD40L expression in mouse splenic T cells. The induction of CD40L on activated mouse splenic CD4+ T cells was differently modulated by &amp;#8710;9-THC, depending on the mode of T cell activation, (i.e., antibodies directed to CD3 and CD28; anti-CD3/CD28 or phorbol ester plus calcium ionophore; PMA/Io). &amp;#8710;9-THC significantly impaired the upregulation of surface CD40L on CD4+ T cells induced by anti-CD3/CD28, but not by PMA/Io. Further, suppression of anti-CD3/CD28-induced CD40L expression in mouse splenic CD4+ T cells by &amp;#8710;9-THC likely occurred at the transcriptional level, independently of CB1, CB2 or GR. The second objective was to investigate the mechanisms by which &amp;#8710;9-THC suppressed CD40L expression by activated primary human CD4+ T cells. Attenuation of anti-CD3/CD28-induced CD40L expression in activated primary human CD4+ T cells by &amp;#8710;9-THC was mediated, at least in part, through suppression of NFAT and NF&amp;#954;B-DNA binding activity. The inhibitory effect of &amp;#916;9-THC on the activation of NFAT and NF&amp;#954;B in primary human CD4+ T cells also involved impairment of Ca2+ elevation without perturbation of proximal T cell receptor signaling events (e.g., tyrosine phosphorylation of ZAP70, Akt, PLC&amp;#947;1/2, and GSK3&amp;#946;). The third objective was to assess the direct effect of &amp;#8710;9-THC on the effector function of primary human B cells using a polyclonal in vitro activation model to generate primary immunoglobulin M (IgM) antibody secreting cells. &amp;#916;9-THC significantly decreased the number of IgM secreting cells, which correlated with the impairment of plasma cell differentiation as evidenced by suppression of immunoglobulin joining chain (IgJ) mRNA expression. &amp;#916;9-THC specifically decreased surface expression of CD80, but not other B cell activation markers (CD69, CD86, and ICAM1). Despite the modest effect on B cell activation, &amp;#916;9-THC profoundly attenuated the proliferation of activated B cells, preventing the progression of B cells toward plasmacytic differentiation. In addition, pretreatment with &amp;#8710;9-THC was accompanied by a robust decrease of STAT3 phosphorylation, whereas the phosphorylation of p65 NF&amp;#954;B subunit was not affected in activated B cells. Collectively, this dissertation research demonstrated that &amp;#8710;9-THC exhibits stimulation- and/or cell type-specific selectivity of NF&amp;#954;B inhibition, and identified several aspects of the multi-faceted mechanism by which &amp;#8710;9-THC suppresses T cell-dependent humoral immunity in humans. A better understanding of the mechanism of cannabinoid-mediated immune function and can be used to address a risk-to-benefit ratio for therapeutic marijuana use.","abstract_has_math":false,"creators":["Ngaotepprutaram, Thitirat"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["KAMINSKI, NORBERT E.","KAPLAN, BARBARA L.F","WAGNER, JAMES","GOUDREAU, JOHN"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013","date_published":"2013","updated_at":"2026-11-18T19:01:52Z","subjects":["B cells","Cellular immunity","Immunology","Pharmacology","T cells","Tetrahydrocannabinol"],"languages":["English"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:836","isbn:9781303007682","isbn:1303007681","oclc:931731650","umi:3557578","local:Ngaotepprutaram_grad.msu_0128D_11876"],"render_values":[{"text":"etd:836","href":null,"code":true},{"text":"isbn:9781303007682","href":null,"code":true},{"text":"isbn:1303007681","href":null,"code":true},{"text":"oclc:931731650","href":null,"code":true},{"text":"umi:3557578","href":null,"code":true},{"text":"local:Ngaotepprutaram_grad.msu_0128D_11876","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/6ahr-1671","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/6ahr-1671","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_836","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["KAMINSKI, NORBERT E.","KAPLAN, BARBARA L.F","WAGNER, JAMES","GOUDREAU, JOHN"]},{"key":"dc:creator","label":"Author","values":["Ngaotepprutaram, Thitirat"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["Text","Theses"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["B cells","Cellular immunity","Immunology","Pharmacology","T cells","Tetrahydrocannabinol"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:836","isbn:9781303007682","isbn:1303007681","oclc:931731650","umi:3557578","local:Ngaotepprutaram_grad.msu_0128D_11876","https://doi.org/doi:10.25335/6ahr-1671"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["&#916;9-tetrahydrocannabinol (&#916;9-THC), the main psychoactive congener in marijuana, modulates a variety of immunological responses, of which humoral immune responses against T cell antigens are particularly sensitive to suppression by &#916;9-THC. Among different types of contact-mediated B cell activation, the CD40-CD40L interaction between B cells and activated CD4+ T cells plays an important role in all stages involved in plasma cell differentiation. Given that both B cells and activated CD4+ T cells are crucial for T cell-dependent humoral immune response, it is important to assess the effects of &#8710;9-THC on both the indirect suppression of accessory T-cell function and/or the direct suppression of B-cell function. The ultimate goal of this project was to identify potential molecular targets responsible for &#916;9-THC-impairment of signal transduction cascades and gene expression during lymphocyte activation by testing the following hypothesis: &#916;9-THC attenuates the human T cell-dependent IgM antibody response by suppression of CD40L upregulation in activated CD4+ T cells and impairment of the CD40-mediated B cell activation. Therefore, the objectives of the present studies were three-fold; of which the first two objectives focused on T cells, whereas the third objective focused on B cells. The first objective investigated the effects of &#8710;9-THC and the involvement of cannabinoid receptor (CB) 1, CB2, and glucocorticoid receptor (GR) on CD40L expression in mouse splenic T cells. The induction of CD40L on activated mouse splenic CD4+ T cells was differently modulated by &#8710;9-THC, depending on the mode of T cell activation, (i.e., antibodies directed to CD3 and CD28; anti-CD3/CD28 or phorbol ester plus calcium ionophore; PMA/Io). &#8710;9-THC significantly impaired the upregulation of surface CD40L on CD4+ T cells induced by anti-CD3/CD28, but not by PMA/Io. Further, suppression of anti-CD3/CD28-induced CD40L expression in mouse splenic CD4+ T cells by &#8710;9-THC likely occurred at the transcriptional level, independently of CB1, CB2 or GR. The second objective was to investigate the mechanisms by which &#8710;9-THC suppressed CD40L expression by activated primary human CD4+ T cells. Attenuation of anti-CD3/CD28-induced CD40L expression in activated primary human CD4+ T cells by &#8710;9-THC was mediated, at least in part, through suppression of NFAT and NF&#954;B-DNA binding activity. The inhibitory effect of &#916;9-THC on the activation of NFAT and NF&#954;B in primary human CD4+ T cells also involved impairment of Ca2+ elevation without perturbation of proximal T cell receptor signaling events (e.g., tyrosine phosphorylation of ZAP70, Akt, PLC&#947;1/2, and GSK3&#946;). The third objective was to assess the direct effect of &#8710;9-THC on the effector function of primary human B cells using a polyclonal in vitro activation model to generate primary immunoglobulin M (IgM) antibody secreting cells. &#916;9-THC significantly decreased the number of IgM secreting cells, which correlated with the impairment of plasma cell differentiation as evidenced by suppression of immunoglobulin joining chain (IgJ) mRNA expression. &#916;9-THC specifically decreased surface expression of CD80, but not other B cell activation markers (CD69, CD86, and ICAM1). Despite the modest effect on B cell activation, &#916;9-THC profoundly attenuated the proliferation of activated B cells, preventing the progression of B cells toward plasmacytic differentiation. In addition, pretreatment with &#8710;9-THC was accompanied by a robust decrease of STAT3 phosphorylation, whereas the phosphorylation of p65 NF&#954;B subunit was not affected in activated B cells. Collectively, this dissertation research demonstrated that &#8710;9-THC exhibits stimulation- and/or cell type-specific selectivity of NF&#954;B inhibition, and identified several aspects of the multi-faceted mechanism by which &#8710;9-THC suppresses T cell-dependent humoral immunity in humans. A better understanding of the mechanism of cannabinoid-mediated immune function and can be used to address a risk-to-benefit ratio for therapeutic marijuana use.","Thesis (Ph. D.)--Michigan State University. Pharmacology & Toxicology-Environmental Toxicology, 2013","Includes bibliographical references (pages 154-194)"]},{"key":"dc:format","label":"Dc Format","values":["xix, 194 pages","application/pdf"]},{"key":"dc:title","label":"Title","values":["Suppression of the T-cell dependent humoral immune response by Delta(9)-tetrahydrocannanbinol involves inpairment of CD40-CD40 ligand interaction"]}]}],"canonical_facts":{"dc:contributor":["KAMINSKI, NORBERT E.","KAPLAN, BARBARA L.F","WAGNER, JAMES","GOUDREAU, JOHN"],"dc:creator":["Ngaotepprutaram, Thitirat"],"dc:date":["2013"],"dc:description":["&#916;9-tetrahydrocannabinol (&#916;9-THC), the main psychoactive congener in marijuana, modulates a variety of immunological responses, of which humoral immune responses against T cell antigens are particularly sensitive to suppression by &#916;9-THC. Among different types of contact-mediated B cell activation, the CD40-CD40L interaction between B cells and activated CD4+ T cells plays an important role in all stages involved in plasma cell differentiation. Given that both B cells and activated CD4+ T cells are crucial for T cell-dependent humoral immune response, it is important to assess the effects of &#8710;9-THC on both the indirect suppression of accessory T-cell function and/or the direct suppression of B-cell function. The ultimate goal of this project was to identify potential molecular targets responsible for &#916;9-THC-impairment of signal transduction cascades and gene expression during lymphocyte activation by testing the following hypothesis: &#916;9-THC attenuates the human T cell-dependent IgM antibody response by suppression of CD40L upregulation in activated CD4+ T cells and impairment of the CD40-mediated B cell activation. Therefore, the objectives of the present studies were three-fold; of which the first two objectives focused on T cells, whereas the third objective focused on B cells. The first objective investigated the effects of &#8710;9-THC and the involvement of cannabinoid receptor (CB) 1, CB2, and glucocorticoid receptor (GR) on CD40L expression in mouse splenic T cells. The induction of CD40L on activated mouse splenic CD4+ T cells was differently modulated by &#8710;9-THC, depending on the mode of T cell activation, (i.e., antibodies directed to CD3 and CD28; anti-CD3/CD28 or phorbol ester plus calcium ionophore; PMA/Io). &#8710;9-THC significantly impaired the upregulation of surface CD40L on CD4+ T cells induced by anti-CD3/CD28, but not by PMA/Io. Further, suppression of anti-CD3/CD28-induced CD40L expression in mouse splenic CD4+ T cells by &#8710;9-THC likely occurred at the transcriptional level, independently of CB1, CB2 or GR. The second objective was to investigate the mechanisms by which &#8710;9-THC suppressed CD40L expression by activated primary human CD4+ T cells. Attenuation of anti-CD3/CD28-induced CD40L expression in activated primary human CD4+ T cells by &#8710;9-THC was mediated, at least in part, through suppression of NFAT and NF&#954;B-DNA binding activity. The inhibitory effect of &#916;9-THC on the activation of NFAT and NF&#954;B in primary human CD4+ T cells also involved impairment of Ca2+ elevation without perturbation of proximal T cell receptor signaling events (e.g., tyrosine phosphorylation of ZAP70, Akt, PLC&#947;1/2, and GSK3&#946;). The third objective was to assess the direct effect of &#8710;9-THC on the effector function of primary human B cells using a polyclonal in vitro activation model to generate primary immunoglobulin M (IgM) antibody secreting cells. &#916;9-THC significantly decreased the number of IgM secreting cells, which correlated with the impairment of plasma cell differentiation as evidenced by suppression of immunoglobulin joining chain (IgJ) mRNA expression. &#916;9-THC specifically decreased surface expression of CD80, but not other B cell activation markers (CD69, CD86, and ICAM1). Despite the modest effect on B cell activation, &#916;9-THC profoundly attenuated the proliferation of activated B cells, preventing the progression of B cells toward plasmacytic differentiation. In addition, pretreatment with &#8710;9-THC was accompanied by a robust decrease of STAT3 phosphorylation, whereas the phosphorylation of p65 NF&#954;B subunit was not affected in activated B cells. Collectively, this dissertation research demonstrated that &#8710;9-THC exhibits stimulation- and/or cell type-specific selectivity of NF&#954;B inhibition, and identified several aspects of the multi-faceted mechanism by which &#8710;9-THC suppresses T cell-dependent humoral immunity in humans. A better understanding of the mechanism of cannabinoid-mediated immune function and can be used to address a risk-to-benefit ratio for therapeutic marijuana use.","Thesis (Ph. D.)--Michigan State University. Pharmacology & Toxicology-Environmental Toxicology, 2013","Includes bibliographical references (pages 154-194)"],"dc:format":["xix, 194 pages","application/pdf"],"dc:identifier":["etd:836","isbn:9781303007682","isbn:1303007681","oclc:931731650","umi:3557578","local:Ngaotepprutaram_grad.msu_0128D_11876","https://doi.org/doi:10.25335/6ahr-1671"],"dc:language":["English"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["B cells","Cellular immunity","Immunology","Pharmacology","T cells","Tetrahydrocannabinol"],"dc:title":["Suppression of the T-cell dependent humoral immune response by Delta(9)-tetrahydrocannanbinol involves inpairment of CD40-CD40 ligand interaction"],"dc:type":["Text","Theses"]},"updated_at":"2026-11-18T19:01:52Z"}